肺表面活性物质治疗新生儿呼吸窘迫综合征  

Clinical Observation on Curing Neonatal Respiratory Distress Syndrome with Pulmonary Sunfactant

作　　者：兰黎[1] 夏传雄[1] 刘亚玲[1] 徐崇民[1] 

机构地区：[1]华中科技大学同济医学院附属协和医院儿科,武汉430022

出　　处：《医药导报》2003年第11期788-790,共3页Herald of Medicine

摘　　要：目的 :探讨肺表面活性物质治疗新生儿呼吸窘迫综合征 (NRDS)的有效性及临床价值。方法 :用肺表面活性物质首剂 12 0mg ,给药时间为出生后 3～ 16h ,平均 (5 .9± 3 .2 )h ,12h后再用 12 0mg。分右侧卧、左侧卧、平卧 3个体位各 1 3剂量 ,每注入 1 3剂量后用复苏气囊供氧 1～ 3min ,使药液在肺内均匀分布 ,约 10min完成注药过程。结果 :用药后即刻症状和体征改善 ,血气分析明显好转 ,吸入氧浓度降低 ,48h内X线胸片明显改善。结论 :肺表面活性物质对NRDS疗效肯定 ,在改善氧气交换和肺部病变方面发挥重要作用。Objective:To study the efficacy and clinical value of pulmonary surfactant (curosurf) replacement therapy in newborn infants with respiratory distress syndrome (NRDS). Method:In the 15 cases of NRDS cured with pulmonary sunfactant, we observed the changes of clinical manifestations, the results of blood gas, fraction of inspiratory oxygen (FiO_2 )and X-ray presentations of lungs after treatment. Results:The symptoms and signs of patients were improved quickly. The results of blood gas analysis were also improved, FiO_2 decreased remarkably, the X-ray pathological changes in the breast of patients were improved evidently. Conclusion:Pulmonary sunfactant has definite effect on neonatal respiratory distress syndrome and plays an important role in improving oxygen exchange and pathological changes in the lungs.

关 键 词：肺表面活性物质 呼吸窘迫综合征/新生儿 

分 类 号：R974[医药卫生—药品] R722.12[医药卫生—药学]